chevron_leftBack
As of 13 June 2026, Lucid Diagnostics Inc. has a market cap of $194.33M USD, ranking #21257 globally and #3462 in the United States.
It ranks #1901 in the Healthcare sector, and #392 in the Medical Devices industry.
Key Stats
Market Cap
$194.33MUSD
Enterprise Value
$185.4MUSD
Revenue (TTM)
$4.71MUSD
EBITDA (TTM)
-$48.77MUSD
Net Income (TTM)
-$70.57MUSD
PS Ratio
41.5
PB Ratio
17.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Lishan Aklog
open_in_new
Employees
82
Founded
2018
IPO
14 Oct 2021
Website
luciddx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1% | -21% | -8% | -11% | -19% | -20% |
News
Loading...
LUCD Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
LUCD
Lucid Diagnostics Inc
ISIN: US54948X1090
Shares Out.:
Shares Outstanding:
203.067M1
Shares Float:
159.971M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.03 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company’s flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: TMO
|
$173.27B
89K%
|
25.8
|
|
NASDAQ: ISRG
|
$160.73B
83K%
|
56.7
|
|
NYSE: ABT
|
$159.07B
82K%
|
25.6
|
|
NYSE: DHR
|
$126.55B
65K%
|
34.7
|
|
NYSE: SYK
|
$120.69B
62K%
|
38.3
|
|
NYSE: BSX
|
$84.93B
44K%
|
24.5
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: MDT
|
$101.9B
52K%
|
22.2
|
|
EPA: EL
|
$97.46B
50K%
84.32B EUR
|
36.7
|
|
TSE: 7741
|
$61.41B
32K%
9.83T JPY
|
40.0
|
|
XETRA: SHL
|
$45.47B
23K%
39.34B EUR
|
18.7
|
|
SIX: ALC
|
$36.38B
19K%
28.99B CHF
|
37.9
|
|
|
$30.06B
15K%
203.66B CNY
|
26.0
|
chevron_leftBack